Drug Interaction Study of Fimasartan/Amlodipine/Hydrochlorothiazide in Healthy Male Subjects
NCT ID: NCT03390465
Last Updated: 2018-08-10
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
36 participants
INTERVENTIONAL
2017-12-15
2018-01-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study to Evaluate the Pharmacokinetic Drug Interaction After Oral Concurrent Administration of Fimasartan and Amlodipine in Healthy Male Volunteers
NCT00938197
A Study to Evaluate the Safety and Pharmacokinetics After Oral Concurrent Administration of Fimasartan and Hydrochlorothiazide in Healthy Male Volunteers
NCT00923533
A Clinical Trial to Evaluate the Pharmacokinetics and Safety of Fimasartan and Amlodipine in Healthy Male Subjects
NCT02920047
Study to Evaluate the Pharmacokinetic Interaction and Safety After Multiple Oral Doses of Fimasartan/Amlodipine and Rosuvastatin in Healthy Male Subjects
NCT02397538
Study of Multiple Oral Dosing to Evaluate the Safety and the Pharmacokinetic Drug-drug Interaction of Telmisartan/Amlodipine and Rosuvastatin in Healthy Male Volunteers
NCT02933658
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Arm1(N=6)
Fimasartan/Amlodipine combination drug, Hydrochlorothiazide
Fimasartan/Amlodipine combination drug, Hydrochlorothiazide
Fimasartan/Amlodipine combination drug, Hydrochlorothiazide
Arm2(N=6)
Fimasartan/Amlodipine combination drug, Hydrochlorothiazide
Fimasartan/Amlodipine combination drug, Hydrochlorothiazide
Fimasartan/Amlodipine combination drug, Hydrochlorothiazide
Arm3(N=6)
Fimasartan/Amlodipine combination drug, Hydrochlorothiazide
Fimasartan/Amlodipine combination drug, Hydrochlorothiazide
Fimasartan/Amlodipine combination drug, Hydrochlorothiazide
Arm4(N=6)
Fimasartan/Amlodipine combination drug, Hydrochlorothiazide
Fimasartan/Amlodipine combination drug, Hydrochlorothiazide
Fimasartan/Amlodipine combination drug, Hydrochlorothiazide
Arm5(N=6)
Fimasartan/Amlodipine combination drug, Hydrochlorothiazide
Fimasartan/Amlodipine combination drug, Hydrochlorothiazide
Fimasartan/Amlodipine combination drug, Hydrochlorothiazide
Arm6(N=6)
Fimasartan/Amlodipine combination drug, Hydrochlorothiazide
Fimasartan/Amlodipine combination drug, Hydrochlorothiazide
Fimasartan/Amlodipine combination drug, Hydrochlorothiazide
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Fimasartan/Amlodipine combination drug, Hydrochlorothiazide
Fimasartan/Amlodipine combination drug, Hydrochlorothiazide
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Hypersensitivity to ingredient of IP and other medication, food.
* Participation in any other study within 3months.
* History of whole blood donation within 2months and Apheresis 1month.
19 Years
50 Years
MALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Boryung Pharmaceutical Co., Ltd
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Eun-Young Kim
Role: PRINCIPAL_INVESTIGATOR
Inje University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Inje University Busan Paik Hospital
Busan, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
BR1010
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.